Description
A kit of 10 vials of Tirzepatide. Each vial contains 5mg of lyophilized Tirzepatide.
Tirzepatide is a once-weekly injectable medication that activates both GIP and GLP-1 receptors. Those pathways affect appetite, satiety, insulin secretion, and blood-glucose regulation.
It has unusually strong clinical evidence for both type 2 diabetes and obesity. In major randomized trials, tirzepatide produced large reductions in HbA1c and substantially greater weight loss than placebo. In SURMOUNT-1, average weight loss reached roughly 15% to 21% over 72 weeks, depending on dose. Longer-term follow-up showed that substantial weight loss was largely maintained through 176 weeks while treatment continued.
It also performs well against established GLP-1 therapy. In SURPASS-2, tirzepatide lowered both HbA1c and body weight more than semaglutide 1 mg in people with type 2 diabetes.





